Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies

NCT00075478 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00075478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00075478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2003
Completion date
February 2, 2014
Enrollment
87 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia in remission, acute myeloid leukemia in remission, aggressive non-hodgkin lymphoma, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, diffuse large b-cell lymphoma, hematopoietic and lymphoid cell neoplasm, indolent non-hodgkin lymphoma, mantle cell lymphoma, myelodysplastic/myeloproliferative neoplasm, plasma cell myeloma, refractory chronic lymphocytic leukemia, refractory hodgkin lymphoma, waldenstrom macroglobulinemia